Why is Telix Pharmaceuticals stock sliding today?

Telix Pharmaceuticals' stock experienced a 6.7% drop to A$16.66 per share on Monday following the announcement of a binding deal to acquire ITM Isotope Technologies Munich SE. The German company specializing in radioisotope production was acquired for US$1.65 billion in cash and debt-free terms, with an additional US$700 million contingent payment contingent upon meeting regulatory and commercial milestones for ITM's lead drug candidate.

The upfront payment consisted of around US$1.25 billion in newly issued Telix shares, priced at the 30-day volume-weighted average of A$16.65, along with ITM's net debt amounting to roughly US$302 million and associated transaction costs. This equity-heavy financing structure sparked concerns among investors about potential dilution, as the deal expanded Telix's share count by approximately 31%.

Consequently, existing shareholders now own around 76.3% of the enlarged company, while ITM's former owners receive about 23.7%. Some market analysts also pointed out that Telix operates at elevated valuation multiples and remains cash-flow negative, making the acquisition of ITM's profitable isotope business at roughly six times its 2025 revenue a substantial financial challenge.

Additionally, profit-taking contributed to the decline, as Telix's stock had surged the previous week on optimism regarding the U.S. FDA's approval of its brain cancer screening treatment. Despite this, the broader Australian equity market did not provide much support, with the S&P/ASX 200 trading slightly positive on the day.